The monarcHER Trial in Advanced HR+, HER2+ Breast Cancer

December 13, 2019
Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, discusses the results of the monarcHER trial, which examined adding the CDK4/6 inhibitor abemaciclib and endocrine therapy to trastuzumab versus trastuzumab plus chemotherapy in advanced hormone receptor-positive, HER2-positive breast cancer.